Navigation path

Additional tools

  • Print version
  • Decrease text
  • Increase text
  • Choose high contrast version
  • Choose standard colour version

Profile of registrant

Novartis International AG

Identification number in the register: 91269481588-28
Registration date: 27/04/09 12:01:53

The information on this organisation was last modified on 01/04/14 11:22:53
The date of the last annual update was 01/04/14 11:22:53

Registrant : Organisation or self-employed individual

Name/company name: Novartis International AG
Legal status: Corporation
Website address:


Section: II - In-house lobbyists and trade/professional associations
and more precisely: Companies & groups

Person with legal responsibility

Surname, Name: Mr  Joseph Jimenez
Position: Chief Executive Officer

Permanent person in charge of EU relations

Surname, Name: Mr  Andras Fehervary
Position: Head of Government & Public Affairs Europe

Contact details:

Contact details of organisation's head office: 1 Novartis International AG Forum 1
Basel CH-4002
Telephone number: (+41) 61 324 11 11
Fax number: (+) 
Other contact information: Novartis European Public Affairs
Rue du Trone, 108
B-1050 Brussels
Tel: +32 2 246 1975

Goals / remit

Goals / remit of the organisation: Our mission is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in generics, eyecare, vaccines and consumer health products.
In 2008, Novartis invested USD 7.2 billion in R&D activities. This is one of the highest figures in the industry relative to net sales (17.4%).
With approximately 130 000 associates in 140 countries worldwide, Novartis associates share a vision of a better today and tomorrow for patients.
Novartis puts patients first. We want to create value for all patients, including those who cannot afford treatment.
During 2008, medicines and vaccines from Novartis treated and protected more than (estimated) 850 million people around the world. Novartis contributed treatments worth USD 1.26 billion through access-to-medicine programs, reaching 74 million patients in need.
The organisation's fields of interests are:
  • global

Number of persons engaged in activities falling under the scope of the Transparency Register

Number of persons: 6
Complementary information:

Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Joaquin de Santos 11/03/14 07/03/15
Maximilian Alexander GÖTZ VON OLENHUSEN 23/01/14 21/01/15
Lea Pfefferle 08/03/14 06/09/14
Joerg Jenewein 07/12/13 05/12/14


Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:

At European level, Novartis is committed to working in partnership with the institutions of the European Union to support policies and actions that improve healthcare and foster the competitiveness of European Industry.

Fields of interest for e-mail alerts on consultations and roadmaps;

Fields declared by the organisation:
  • Competition
  • Consumer Affairs
  • Customs
  • Development
  • Economic and Financial Affairs
  • Employment and Social Affairs
  • Enlargement
  • Enterprise
  • Environment
  • External Relations
  • Food Safety
  • General and Institutional Affairs
  • Home Affairs
  • Information Society
  • Internal Market
  • Justice and Fundamental Rights
  • Public Health
  • Regional Policy
  • Research and Technology
  • Taxation
  • Trade


Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.

Member of EFPIA, EBE, EVM, EuropaBio, EGA, AESGP, EUROMCONTACT, CEFIC, BusinessEurope (Economiesuisse), EDMA, Eucomed, BritCham.

Financial data

Financial year: 01/2012 - 12/2012
Estimated costs to the organisation directly related to representing interests to EU institutions in that year: 600000  € - 700000  €
Amount and source of funding received from the EU institutions in financial year n-1 of registration
Procurement: 0 €
Grants: 0 €
Other (financial) information provided by the organisation:

The estimated costs are calculated based on the proportion of working time spent by Novartis associates on representing interests to the EU institutions in 2012. This proportion is applied to the overall personnel and overhead costs.

Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.